Medicus Pharma Launches Genomics-Based Endometriosis Trial in UAE

Jun 11, 2026

Medicus Pharma (NASDAQ: MDCX) announced the submission of an investigational new drug (IND) application to the Department of Health Abu Dhabi for PRECISION E2, a first-of-its-kind Phase 2a genomics-enabled clinical trial evaluating Teverelix in women suffering from symptomatic endometriosis in the United Arab Emirates.

The study will combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic data, and genomic analysis to better understand treatment response variability. By leveraging participants enrolled in the Emirati Genome Program, one of the world’s largest national genomics initiatives, Medicus aims to explore how genetic differences may influence response to hormonal therapies for endometriosis.

#MedicusPharma
#MDCX
#Endometriosis
#Biotech
#ClinicalTrials
#PrecisionMedicine
#Genomics
#WomensHealth
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#UAE
#EmiratiGenomeProgram
#JaneKing
#NewsOut